Clarivate published the company’s annual “Drugs to Watch” list, and cited several medicines that the analysts expect to be blockbusters – projected to bring in $1 billion in sales annually.
Entresto granted expanded indication in chronic heart failure by FDABlockbusters, Chronic Heart Failure, Expanded Indication, FDA, Heart Failure with Preserved Ejection Fraction (HFpEF), Heart Failure with Reduced Ejection Fraction (HFrEF), Label Expansion, Left Ventricular Ejection Fraction (LVEF), Novartis, Therapeutics
Novartis’ Entresto is the first therapy approved in the United States to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF).
The U.S. Food and Drug Administration approved Merck & Co. and Bayer AG’s heart failure drug Verquvo (vericiguat), an orally administered soluble guanylate cyclase stimulator.
FDA Action Alert: Merck, Aurinia and AmgenAmgen, Business, Calcineurin Inhibitors (CNI), Chronic Heart Failure, Clinical Trials, Collaborations, Deals, FDA, FDA, Hematopoietic Syndrome of Acute Radiation Syndrome (H-ARS), Lupus nephritis, Merck, Myelosuppression, New Drug Application (NDA), PDUFA, Priority Review, R&D, Systemic Lupus Erythematosus (SLE)
After a start-of-the-year lull, activities at the U.S. Food and Drug Administration are starting to pick up, according to BioSpace.
Merck & Co. Inc.’s experimental treatment vericiguat being developed with Bayer AG for patients with worsening chronic heart failure met the main goal of a late-stage study.